Half Year Trading Update

AI SummaryClose X

Allergy Therapeutics plc reported a strong first half with expected revenues of £36.3 million, a 7% increase on a reported basis, despite phasing out German TAV products, and anticipates full-year revenue growth exceeding the prior year. The company's cash position stood at £10.1 million as of December 31, 2025, following the repayment of shareholder loans, and it has access to £70 million in uncommitted funding. Commercialisation of Grassmuno®, the first new grass pollen immunotherapy in Germany in twenty years, commenced in January 2026, following regulatory approval in December 2025, with sales momentum expected to accelerate.

Disclaimer*

UK 100

Latest directors dealings